Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC (NCT02273375)

🧪 Interventions in This Study

• MEDI4736 (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (271 Sites)

Showing the first 25 of 271 sites.

• Banner MD Anderson Cancer Center — Gilbert, Arizona
• USC Norris/Comprehensive Cancer Centre — Los Angeles, California
• National Jewish Health — Denver, Colorado
• University of Florida — Gainesville, Florida
• H. Lee Moffitt Cancer Center — Tampa, Florida
• Duke University Medical Center — Durham, North Carolina
• Hematology and Oncology Associates of NEPA — Dunmore, Pennsylvania
• Thomas Jefferson University — Philadelphia, Pennsylvania
• The Reading Hospital Medical Center — West Reading, Pennsylvania
• Campbelltown Hospital — Campbelltown, New South Wales
• Chris O'Brien Lifehouse — Camperdown, New South Wales
• Coffs Habour Health Campus - NCCI — Coffs Harbour, New South Wales
• Gosford Hospital — Gosford, New South Wales
• Nepean Hospital — Kingswood, New South Wales
• St. George Hospital, Cancer Care Centre — Kogarah, New South Wales
• Liverpool Cancer Therapy Centre, Liverpool Hospital — Liverpool, New South Wales
• Northern Cancer Institute St Leonards — St Leonards, New South Wales
• Westmead Hospital — Westmead, New South Wales
• Sunshine Coast University Hospital — Birtinya, Queensland
• Princess Alexandra Hospital — Brisbane, Queensland
• The Prince Charles Hospital — Chermside, Queensland
• Royal Adelaide Hospital — Adelaide, South Australia
• Mater Medical Centre — Brisbane, South, QLD
• Royal Hobart Hospital — Hobart, Tasmania
• Monash Medical Centre — Clayton, Victoria

📞 Contact the Study Coordinator

Phone: (877) 632-6789

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-Small Cell Lung Cancer

• Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
• PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
• Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Chandler, Arizona

Explore by condition: All Non-Small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.